Liabilities and Equity in USD of Intra-Cellular Therapies, Inc. from Q4 2012 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Summary
Intra-Cellular Therapies, Inc. quarterly Liabilities and Equity history and change rate from Q4 2012 to Q4 2024.
  • Intra-Cellular Therapies, Inc. Liabilities and Equity for the quarter ending 31 Dec 2024 was $1.37B, a 87.7% increase year-over-year.
Liabilities and Equity, Quarterly (USD)
Liabilities and Equity, YoY Quarterly Change (%)

Intra-Cellular Therapies, Inc. Quarterly Liabilities and Equity (USD)

Period Value YoY Chg Change % Date Report Filed
Q4 2024 $1.37B +$639M +87.7% 31 Dec 2024 10-K 21 Feb 2025
Q3 2024 $1.32B +$607M +84.5% 30 Sep 2024 10-Q 30 Oct 2024
Q2 2024 $1.32B +$607M +85% 30 Jun 2024 10-Q 07 Aug 2024
Q1 2024 $747M +$24.9M +3.45% 31 Mar 2024 10-Q 07 May 2024
Q4 2023 $728M -$26.5M -3.51% 31 Dec 2023 10-K 21 Feb 2025
Q3 2023 $718M -$64.3M -8.23% 30 Sep 2023 10-Q 02 Nov 2023
Q2 2023 $714M -$98.3M -12.1% 30 Jun 2023 10-Q 03 Aug 2023
Q1 2023 $722M -$146M -16.9% 31 Mar 2023 10-Q 04 May 2023
Q4 2022 $755M +$265M +54.1% 31 Dec 2022 10-K 22 Feb 2024
Q3 2022 $782M +$225M +40.4% 30 Sep 2022 10-Q 03 Nov 2022
Q2 2022 $812M +$186M +29.8% 30 Jun 2022 10-Q 09 Aug 2022
Q1 2022 $869M +$194M +28.8% 31 Mar 2022 10-Q 10 May 2022
Q4 2021 $490M -$227M -31.7% 31 Dec 2021 10-K 01 Mar 2023
Q3 2021 $557M -$214M -27.8% 30 Sep 2021 10-Q 09 Nov 2021
Q2 2021 $626M +$185M +41.9% 30 Jun 2021 10-Q 09 Aug 2021
Q1 2021 $674M +$193M +40.2% 31 Mar 2021 10-Q 10 May 2021
Q4 2020 $717M +$466M +186% 31 Dec 2020 10-K 01 Mar 2022
Q3 2020 $771M +$491M +175% 30 Sep 2020 10-Q 09 Nov 2020
Q2 2020 $441M +$131M +42.3% 30 Jun 2020 10-Q 10 Aug 2020
Q1 2020 $481M +$138M +40.3% 31 Mar 2020 10-Q 07 May 2020
Q4 2019 $251M -$106M -29.7% 31 Dec 2019 10-K 25 Feb 2021
Q3 2019 $281M -$105M -27.2% 30 Sep 2019 10-Q 05 Nov 2019
Q2 2019 $310M -$102M -24.8% 30 Jun 2019 10-Q 07 Aug 2019
Q1 2019 $343M -$103M -23% 31 Mar 2019 10-Q 08 May 2019
Q4 2018 $357M -$114M -24.2% 31 Dec 2018 10-K 02 Mar 2020
Q3 2018 $386M +$51.4M +15.4% 30 Sep 2018 10-Q 07 Nov 2018
Q2 2018 $412M +$62.5M +17.9% 30 Jun 2018 10-Q 02 Aug 2018
Q1 2018 $446M +$73.3M +19.7% 31 Mar 2018 10-Q 03 May 2018
Q4 2017 $471M +$82.6M +21.2% 31 Dec 2017 10-K 27 Feb 2019
Q3 2017 $334M -$208M -38.4% 30 Sep 2017 10-Q 08 Nov 2017
Q2 2017 $350M -$98.1M -21.9% 30 Jun 2017 10-Q 09 Aug 2017
Q1 2017 $372M -$91.4M -19.7% 31 Mar 2017 10-Q 10 May 2017
Q4 2016 $389M -$95.2M -19.7% 31 Dec 2016 10-K 01 Mar 2018
Q3 2016 $543M +$29.4M +5.74% 30 Sep 2016 10-Q 09 Nov 2016
Q2 2016 $448M +$234M +110% 30 Jun 2016 10-Q 04 Aug 2016
Q1 2016 $464M +$227M +95.5% 31 Mar 2016 10-Q 28 Apr 2016
Q4 2015 $484M +$353M +269% 31 Dec 2015 10-K 01 Mar 2017
Q3 2015 $513M +$376M +273% 30 Sep 2015 10-Q 05 Nov 2015
Q2 2015 $213M +$72.1M +51% 30 Jun 2015 10-Q 05 Aug 2015
Q1 2015 $237M +$90.5M +61.7% 31 Mar 2015 10-Q 30 Apr 2015
Q4 2014 $131M +$92.7M +241% 31 Dec 2014 10-K 25 Feb 2016
Q3 2014 $138M +$90.3M +191% 30 Sep 2014 10-Q 03 Nov 2014
Q2 2014 $141M +$141M 30 Jun 2014 10-Q 12 Aug 2014
Q1 2014 $147M +$147M 31 Mar 2014 10-Q 05 May 2014
Q4 2013 $38.4M +$18.6M +94% 31 Dec 2013 10-K 12 Mar 2015
Q3 2013 $47.3M 30 Sep 2013 10-Q 05 Nov 2013
Q2 2013 $49.00* 30 Jun 2013 10-Q 15 Aug 2013
Q1 2013 $4.07K* 31 Mar 2013 10-Q 15 Aug 2013
Q4 2012 $19.8M 31 Dec 2012 10-K 25 Mar 2014
* An asterisk sign (*) next to the value indicates that the value is likely invalid.